Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Otto Wilhelm Merten"'
Autor:
Otto-Wilhelm Merten
Publikováno v:
Microorganisms, Vol 12, Iss 2, p 384 (2024)
Today, recombinant adeno-associated virus (rAAV) vectors represent the vector systems which are mostly used for in vivo gene therapy for the treatment of rare and less-rare diseases. Although most of the past developments have been performed by using
Externí odkaz:
https://doaj.org/article/073c5a697d48439eb7f100ac376f9d74
Autor:
Lionel Galibert, Aurélien Jacob, Adrien Savy, Yohann Dickx, Delphine Bonnin, Christophe Lecomte, Lise Rivollet, Peggy Sanatine, Marjorie Boutin Fontaine, Christine Le Bec, Otto-Wilhelm Merten
Publikováno v:
Microorganisms, Vol 9, Iss 9, p 1799 (2021)
Large-scale manufacturing of rAAV is a bottleneck for the development of genetic disease treatments. The baculovirus/Sf9 cell system underpins the first rAAV treatment approved by EMA and remains one of the most advanced platforms for rAAV manufactur
Externí odkaz:
https://doaj.org/article/4577bcd650f74a5eb809f151a65eb0f0
Autor:
Lionel Galibert, Adrien Savy, Yohann Dickx, Delphine Bonnin, Bérangère Bertin, Isidore Mushimiyimana, Monique M van Oers, Otto-Wilhelm Merten
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207414 (2018)
The ability to produce large quantities of recombinant Adeno-Associated Virus (rAAV) vectors is an important factor for the development of gene therapy-based medicine. The baculovirus/insect cell expression system is one of the major systems for larg
Externí odkaz:
https://doaj.org/article/b9f1f2eb1c3f487d8435a50d385510d6
Autor:
Adrien Savy, Minna U Kaikkonen, Adrien Léger, Yohann Dickx, Lionel Galibert, Otto-Wilhelm Merten
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0199866 (2018)
The human Adeno-Associated Virus serotype 2 (wtAAV2) is a common non-pathological virus and its recombinant form (rAAV) is widely used as gene therapy vector. Although rAAVs are routinely produced in the Baculovirus/Sf9 cell system, wtAAV2 has never
Externí odkaz:
https://doaj.org/article/b8e1cb9584bf4ab098e58d05e3885947
Autor:
Otto-Wilhelm Merten, J Fraser Wright
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Externí odkaz:
https://doaj.org/article/6c683722dc9941858b0f01ee07e40a85
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Lentiviral vectors (LV) have seen considerably increase in use as gene therapy vectors for the treatment of acquired and inherited diseases. This review presents the state of the art of the production of these vectors with particular emphasis on thei
Externí odkaz:
https://doaj.org/article/a0091945a79243bc89bf573557919464
Autor:
Emilie Lecomte, Benoît Tournaire, Benjamin Cogné, Jean-Baptiste Dupont, Pierre Lindenbaum, Mélanie Martin-Fontaine, Frédéric Broucque, Cécile Robin, Matthias Hebben, Otto-Wilhelm Merten, Véronique Blouin, Achille François, Richard Redon, Philippe Moullier, Adrien Léger
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Recent successful clinical trials with recombinant adeno-associated viral vectors (rAAVs) have led to a renewed interest in gene therapy. However, despite extensive developments to improve vector-manufacturing processes, undesirable DNA contaminants
Externí odkaz:
https://doaj.org/article/741f46340a074fda945084019638521d
Autor:
Benoit Delache, Bérangère Bertin, Jack-Yves Deschamps, Virginie Latournerie, Carole Masurier, Christian Leborgne, Sophie Moullec, Olivier Benveniste, Roger Le Grand, Philippe Moullier, Fanny Collaud, Sylvie Boutin, Otto Wilhelm Merten, Philippe Veron, Laetitia van Wittenberghe, Yves Fromes, Nathalie Dereuddre-Bosquet, Federico Mingozzi
Publikováno v:
Scientific Reports
Scientific Reports, Nature Publishing Group, 2020, 10 (1), pp.864. ⟨10.1038/s41598-020-57893-z⟩
Scientific Reports, 2020, 10 (1), pp.864. ⟨10.1038/s41598-020-57893-z⟩
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports, Nature Publishing Group, 2020, 10 (1), pp.864. ⟨10.1038/s41598-020-57893-z⟩
Scientific Reports, 2020, 10 (1), pp.864. ⟨10.1038/s41598-020-57893-z⟩
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Neutralizing antibodies directed against adeno-associated virus (AAV) are commonly found in humans. In seropositive subjects, vector administration is not feasible as antibodies neutralize AAV vectors even at low titers. Consequently, a relatively la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::546fe2adb17ce6e26f7d3cb1efb28b38
https://www.hal.inserm.fr/inserm-02489693/file/s41598-020-57893-z.pdf
https://www.hal.inserm.fr/inserm-02489693/file/s41598-020-57893-z.pdf
Autor:
Otto-Wilhelm Merten, Lucile Nauwynck, Yohann Dickx, Lionel Galibert, Adrien Savy, Delphine Bonnin
Publikováno v:
Human Gene Therapy Methods
Hum Gene Ther Methods
Hum Gene Ther Methods, 2017, 28 (5), pp.277-289. ⟨10.1089/hgtb.2016.133⟩
Hum Gene Ther Methods
Hum Gene Ther Methods, 2017, 28 (5), pp.277-289. ⟨10.1089/hgtb.2016.133⟩
International audience; Adeno-associated virus (AAV) inverted terminal repeats (ITRs) are key elements of AAV. These guanine-cytosine-rich structures are involved in the replication and encapsidation of the AAV genome, along with its integration in a
Autor:
Otto-Wilhelm Merten
Publikováno v:
Cell and Gene Therapy Insights. 2:521-551